Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients

Resource type
Journal Article
Authors/contributors
Title
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients
Abstract
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.
Publication
Journal of the Pediatric Infectious Diseases Society
Volume
13
Issue
Supplement_1
Pages
S14-S21
Date
2024-02-01
Journal Abbr
Journal of the Pediatric Infectious Diseases Society
ISSN
2048-7207
Accessed
3/17/24, 10:20 AM
Library Catalog
Silverchair
Citation
Valencia Deray, K. G., Danziger-Isakov, L. A., & Downes, K. J. (2024). Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. Journal of the Pediatric Infectious Diseases Society, 13(Supplement_1), S14–S21. https://doi.org/10.1093/jpids/piad059
DRUGS AND THERAPIES
SOLID ORGANS AND MCSS
HEME-ONC AND CELLULAR THERAPIES
Link to this record